Skip to content

Application of Magnetic Convulsion and Electric Shock Therapy in Depression

Efficacy and mechanism of magnetic tics versus electroconvulsive therapy in the treatment of depression: a randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092049
Enrollment
Unknown
Registered
2024-11-08
Start date
2024-11-11
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

ECT group:Electroconvulsive therapy

Sponsors

Affiliated Kangning Hospital of Ningbo University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-60 years old; 2. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V), two psychiatrists independently diagnose the patients as depression; 3. a total HAMD-24 score of >20; 4. Right-handedness; 5. The patient's physical examination, medical history, vital signs, blood, urine and stool routine, liver and kidney function, electrolytes, electrocardiogram, electroencephalogram and other indicators are normal; 6. After fully understanding the safety of MST, they are willing to actively cooperate with the treatment and have their informed consent signed by themselves and their families.

Exclusion criteria

Exclusion criteria: 1. Age 60 years; 2. Those with a history of severe physical illness and depression due to other psychoactive and non-dependent substances; 3. Patients with metallic or electronic instruments placed in the body, such as intracranial metallic foreign bodies, cochlear implants, pacemakers and stents, and other metallic foreign bodies; 4. Patients at risk for seizures, with previous cranial disease, head trauma, alcoholism, EEG abnormalities, MRI evidence of structural abnormalities in the brain, or a family history of epilepsy; 5. Patients at risk of acute suicide; 6. Those with psychotic symptoms requiring a combination of should antipsychotic medications; 7. Receiving ECT after enrollment; 8. Those who are pregnant, breastfeeding, or planning to become pregnant during the trial; 9. Refusal to sign the informed consent form;

Design outcomes

Primary

MeasureTime frame
Hamilton Anxiety Scale (HAMA) ;Self-rating Depression Scale (SDS) ;Self-rating Anxiety Scale (SAS) ;Baker Suicide Ideation Scale Chinese version (BSI-CV) ;Neuropsychological Status Rating Scale (RBANS) ;

Secondary

MeasureTime frame
Electromyographic changes;Neuroelectrophysiological indicators;Brain-derived neurotrophic factor;Hamilton Depression Scale (HAMD-24) ;

Countries

China

Contacts

Public ContactDongsheng Zhou

Affiliated Kangning Hospital of Ningbo University

wyzhouds@sina.com+86 574 26302565

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026